<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib
Jorge J. Castillo(Dana-Farber Cancer Institute), Steven P. Treon(Dana-Farber Cancer Institute), Christopher J. Patterson(Dana-Farber Cancer Institute), Amanda Kofides(Shaanxi Research Association for Women and Family), Gloria Chan(Shaanxi Research Association for Women and Family), Maria Demos(Shaanxi Research Association for Women and Family), Nicholas Tsakmaklis(Shaanxi Research Association for Women and Family), Maria Luisa Guerrera(Harvard University), Andrew Keezer(Dana-Farber Cancer Institute), Manit Munshi(Dana-Farber Cancer Institute), Joshua Gustine(Boston University), Kirsten Meid(Shaanxi Research Association for Women and Family), Jiaji G. Chen(Shaanxi Research Association for Women and Family), Toni Dubeau(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Lian Xu(Huazhong Agricultural University), Xia Liu(Dana-Farber Cancer Institute), Zachary R. Hunter(Harvard University)
Cited by 103
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Immunopathology of Hyperinflammation in COVID-19
|American Journal Of Pathology|2020|526
Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders
|Clinical Infectious Diseases|2006|270
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
|Journal of Clinical Oncology|2018|176